Filing Details

Accession Number:
0001387131-17-005721
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2017-12-06 15:41:59
Reporting Period:
2017-04-10
Accepted Time:
2017-12-06 15:41:59
Original Submission Date:
2017-04-13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1173281 Ohr Pharmaceutical Inc OHRP () 4/A
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1131362 Orin Hirschman C/O Ohr Pharmaceutical Inc.
800 Third Ave., 11Th Floor
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share Acquisiton 2017-04-10 171,429 $0.70 1,678,177 No 4 P Indirect By AIGH Investment Partners, LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By AIGH Investment Partners, LLC
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrants (right to buy) Acquisiton 2017-04-10 120,001 $0.00 120,001 $1.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
120,001 2017-04-10 2022-04-10 No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share 138,200 Indirect By self as custodian of accounts for the benefit of minor children.
Footnotes
  1. On April 5, 2017, Ohr Pharmaceutical, Inc. (the "Issuer") entered into a securities purchase agreement (the "Securities Purchase Agreement") with various purchasers set forth on the signatures pages thereto, including the Reporting Person. Pursuant to the Securities Purchase Agreement, the Reporting Person purchased shares of the Issuer's common stock (the "Common Stock") and warrants to purchase shares of Common Stock in a registered offering (the "Offering") for an aggregate purchase price of $120,000. The closing of the Offering occurred on April 10, 2017. The form 4 as originally filed underreported the Reporting Person's investment by $20,000, shares of common stock by 28,571, and shares of common stock issuable upon exercise of warrants by 20,000.